Anti-pTau Active Immunotherapy
Alzheimer's Disease (Preclinical)
Phase 2 (Prevention)Partner Trial Launched
Key Facts
Indication
Alzheimer's Disease (Preclinical)
Phase
Phase 2 (Prevention)
Status
Partner Trial Launched
Company
About AC Immune
Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.
View full company profile